Last reviewed · How we verify

NCT03775655

Low Dose Hyperbaric Bupivacaine and Dexmedetomidine as an Adjuvant, Caesarean Section

Completed Phase 2, PHASE3 Last updated 15 January 2019
What this trial tests

Phase 2, PHASE3 trial testing Dexmedetomidine in Cesarean Section in 40 participants. Completed in 10 January 2019.

Timeline
1 September 2018
Primary endpoint
10 January 2019
10 January 2019

Quick facts

Lead sponsorMenoufia University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment40
Start date1 September 2018
Primary completion10 January 2019
Estimated completion10 January 2019
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Menoufia University

Who can join

Adults 18 to 35, female only, with Cesarean Section or Spinal Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the effectiveness of low dose scheme with dexmedetomidine as an adjuvant. Taking in consideration optimum intraoperative surgical conditions, best post-operative pain free experience, and more stable hemodynamic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Cesarean Section

Currently open trials in the same condition.

Other Menoufia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing